What question did this study set out to answer?

To assess the efficacy of astaxanthin supplementation on cardiometabolic risk factors, oxidative stress, and inflammatory markers in overweight and obese adults.

August 16, 2026Nutrition & MetabolismOpen Access

Astaxanthin supplementation and cardiometabolic risk factors in overweight and obese adults: a GRADE-assessed systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

APAijie Pei JXJun Xu XNXia Ni

Discussion

Member takes

Overview

Systematic review finds astaxanthin improves lipid profiles and reduces inflammation in overweight adults, suggesting adjunctive cardiometabolic benefits.

Key Points

To assess the efficacy of astaxanthin supplementation on cardiometabolic risk factors, oxidative stress, and inflammatory markers in overweight and obese adults.
Searched PubMed, Scopus, Embase, Cochrane, and Web of Science through May 2026 for randomized trials.
Meta-analyzed standardized mean differences (SMDs) and weighted mean differences (WMDs) using random-effects models across 16 trials with 694 participants (346 intervention, 348 control).
Evaluated risk of bias using RoB 2.0 and assessed evidence certainty with the GRADE framework.
Astaxanthin significantly reduced malondialdehyde (SMD: -1.75), CRP (SMD: -0.35), IL-6 (SMD: -0.69), triglycerides (WMD: -2.90 mg/dL), total cholesterol (WMD: -2.73 mg/dL), and LDL-C (WMD: -1.09 mg/dL).
Supplementation significantly increased superoxide dismutase (SMD: 1.37), total antioxidant capacity (SMD: 2.31), and HDL-C (WMD: 1.04 mg/dL), with greater lipid improvements at higher doses (≥12 mg/day) and longer durations (≥12 weeks).
No significant alterations were detected for body weight, BMI, TNF-α, or blood pressure, and certainty of evidence across several outcomes was rated low to very low.

Cite This Study

Pei et al. (2026) studied this question.

synapsesocial.com/papers/6a817a91f2fb91fc834ae810 https://doi.org/10.1186/s12986-026-01188-z

View Full Paper

Ask AI

Bookmark

August 16, 2026Nutrition & MetabolismOpen Access

Astaxanthin supplementation and cardiometabolic risk factors in overweight and obese adults: a GRADE-assessed systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

APAijie Pei JXJun Xu XNXia Ni

Discussion

Member takes

Overview

Systematic review finds astaxanthin improves lipid profiles and reduces inflammation in overweight adults, suggesting adjunctive cardiometabolic benefits.

Key Points

To assess the efficacy of astaxanthin supplementation on cardiometabolic risk factors, oxidative stress, and inflammatory markers in overweight and obese adults.
Searched PubMed, Scopus, Embase, Cochrane, and Web of Science through May 2026 for randomized trials.
Meta-analyzed standardized mean differences (SMDs) and weighted mean differences (WMDs) using random-effects models across 16 trials with 694 participants (346 intervention, 348 control).
Evaluated risk of bias using RoB 2.0 and assessed evidence certainty with the GRADE framework.
Astaxanthin significantly reduced malondialdehyde (SMD: -1.75), CRP (SMD: -0.35), IL-6 (SMD: -0.69), triglycerides (WMD: -2.90 mg/dL), total cholesterol (WMD: -2.73 mg/dL), and LDL-C (WMD: -1.09 mg/dL).
Supplementation significantly increased superoxide dismutase (SMD: 1.37), total antioxidant capacity (SMD: 2.31), and HDL-C (WMD: 1.04 mg/dL), with greater lipid improvements at higher doses (≥12 mg/day) and longer durations (≥12 weeks).
No significant alterations were detected for body weight, BMI, TNF-α, or blood pressure, and certainty of evidence across several outcomes was rated low to very low.

Cite This Study

Pei et al. (2026) studied this question.

synapsesocial.com/papers/6a817a91f2fb91fc834ae810 https://doi.org/10.1186/s12986-026-01188-z

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark